NO20006667L - Retinoid-relaterte reseptor funksjonsregulerende middel - Google Patents
Retinoid-relaterte reseptor funksjonsregulerende middelInfo
- Publication number
- NO20006667L NO20006667L NO20006667A NO20006667A NO20006667L NO 20006667 L NO20006667 L NO 20006667L NO 20006667 A NO20006667 A NO 20006667A NO 20006667 A NO20006667 A NO 20006667A NO 20006667 L NO20006667 L NO 20006667L
- Authority
- NO
- Norway
- Prior art keywords
- cachexia
- hydrocarbon group
- insulin
- hydrogen
- optionally substituted
- Prior art date
Links
- 150000004492 retinoid derivatives Chemical class 0.000 title 1
- 206010006895 Cachexia Diseases 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 208000011580 syndromic disease Diseases 0.000 abstract 4
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000017169 kidney disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010054805 Macroangiopathy Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000020764 Sensation disease Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 208000004104 gestational diabetes Diseases 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 230000001631 hypertensive effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 201000009925 nephrosclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En farmasøytisk sammensetning av oppfinnelsen som er en retionoid-relatert reseptorfunksjons- regulerende middel som omfatter en 1,3-azolderivat representert ved formelen (I): hvor R1 er en aromatisk hydrokarbongruppe eller en aromatisk heterosyklisk gruppe, som hver kan substitueres; R2 er hydrogen eller en eventuelt substituert hydrokarbon-gruppe; X ff O, S er en gruppe representert ved formelen: -NR4- hvori R4 er hydrogen eller en eventuelt substituert alkylgruppe; A er en aromatisk hydrokarbon gruppe eller en aromatisk heterosyklisk gruppe, som hver kan substitueres; R3 a en gruppe representert ved formelen: -OR5 hvori R3 er hydrogen eller en eventuelt substituert hydrokarbongruppe, eller -NR*R7 hvori R6 og R7 er den samme eller forskjellig og hver er hydrogen eller en eventuelt substituert hydrokarbongruppe, eller R6 og R7 kan sammen med tilliggende nitrogenatom danne en ring, forutsatt at forbindelsene er representert ved formelen: CH COOH COOH er ekskludert, eller dets salt, er lav i toksisitet, og kan anvendes, for eksempel som et middel for å forebygge eller behandle diabetes (for eksempel, insulinavhengig diabetes, ikke-insulinavhengig diabetes, gestasjonell diabetes), som et middel for å behandle eller hindre hyperlipidemi (for eksempel, hypertriglysemi, hyper-kolesterolemi, hypo-HD-lipoproteinemi), en insulinsensitivitetsforsterkende middel, et insulinresistens forbedrende middel, et middel for å hindre eller behandle svekket glukosetoleranse (IGT) og et middel for å hindre transisjon fra svekket glukose toleranse til diabetes. Videre kan en farmasøytisk sammensetning fra oppfinnelsen bli brukt, for eksempel, som et middel for å hindre eller behandle diabetiske komplikasjoner (for eksempel, neuropati, nefropati, retinopati, katarakt, makroangiopati, osteopeni), fedme, osteoporose, kakeksia, (for eksempel karsinomatøs kakeksia, tuberkulose kakeksia, diabetisk kakeksia, hemopatisk kakeksia, endokrinopatisk kakeksia, infektiøs kakeksia, eller kakeksia indusert ved ervervet immunosvikt syndrom), fettholdig lever, hypertensjon, polysystisk ovarie syndrom, nyresykdommer, for eksempel, diabetisk nefropati, glomulær nefritt, glomulær sklerose, nefrotisk syndrom, hypertensitiv nefrosklerose, terminal renal forstyrrelse (muskulær dystrofi, myokardial infarkt, angina pektoris), cerebral infarkt, insulin resistent syndrom, syndrom X, hyperinsulinemi-indusert sensorisk forstyrrelse, tumor (for eksempel leukemi, brystcancer, prostata cancer, hudcancer), arteriosklerose (for eksempel, aterosklerose) og som et farmasøytisk middel for å kontrollere appetitt og matinntak.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18669898 | 1998-07-01 | ||
| PCT/JP1999/003520 WO2000001679A1 (en) | 1998-07-01 | 1999-06-30 | Retinoid-associated receptor regulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006667D0 NO20006667D0 (no) | 2000-12-27 |
| NO20006667L true NO20006667L (no) | 2001-02-28 |
Family
ID=16193077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006667A NO20006667L (no) | 1998-07-01 | 2000-12-27 | Retinoid-relaterte reseptor funksjonsregulerende middel |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6545009B1 (no) |
| EP (1) | EP1092711A4 (no) |
| KR (1) | KR20010053282A (no) |
| CN (1) | CN1314899A (no) |
| AU (1) | AU4394799A (no) |
| BR (1) | BR9911752A (no) |
| CA (1) | CA2332178A1 (no) |
| HU (1) | HUP0102470A3 (no) |
| ID (1) | ID29247A (no) |
| IL (1) | IL140422A0 (no) |
| LV (1) | LV12633B (no) |
| NO (1) | NO20006667L (no) |
| PL (1) | PL345247A1 (no) |
| SK (1) | SK20182000A3 (no) |
| WO (1) | WO2000001679A1 (no) |
| ZA (1) | ZA200007635B (no) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1394154A4 (en) | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE |
| WO2002085382A1 (en) * | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Methods of treating syndrome x with aliphatic polyamines |
| GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| US20040248863A1 (en) * | 2001-06-22 | 2004-12-09 | Wright Samuel D. | Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflamation |
| WO2003000249A1 (en) * | 2001-06-26 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Function regulator for retinoid relative receptor |
| JP2003081832A (ja) * | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| JP2005516968A (ja) * | 2001-12-29 | 2005-06-09 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用 |
| US7183276B2 (en) | 2002-02-28 | 2007-02-27 | Takeda Pharmaceutical Company Limited | Azole compounds |
| CN1731994A (zh) | 2002-11-01 | 2006-02-08 | 武田药品工业株式会社 | 预防或治疗神经病的药剂 |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| DE10308353A1 (de) * | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5191744B2 (ja) * | 2005-02-25 | 2013-05-08 | ソウル ナショナル ユニバーシティー インダストリー ファンデーション | ペルオキシソーム増殖子活性化受容体デルタリガンドのチアゾール誘導体及びその製造方法 |
| WO2006091047A1 (en) * | 2005-02-25 | 2006-08-31 | Heonjoong Kang | Thiazole derivatives as ppar delta ligands and their manufacturing process |
| CA2623327A1 (en) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| WO2008064136A2 (en) * | 2006-11-17 | 2008-05-29 | Acadia Pharmaceuticals Inc. | Compounds with activity at retinoic acid receptors |
| US8207196B2 (en) | 2007-02-02 | 2012-06-26 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9233941B2 (en) | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
| US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
| US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9085566B2 (en) | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
| EP2786993B1 (en) | 2007-08-13 | 2017-11-15 | Monsanto Technology LLC | Compositions and methods for controlling nematodes |
| WO2011011105A2 (en) * | 2009-05-07 | 2011-01-27 | Baylor College Of Medicine | Traceable retinoid acid for imaging, disease prevention and therapy |
| GB0915196D0 (en) | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| WO2012028100A1 (en) * | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| KR20170096181A (ko) | 2014-12-19 | 2017-08-23 | 갈데르마 리써어치 앤드 디벨로프먼트 | 신규 화합물, 이의 합성 방법 및 의약 및 화장품에서의 이의 용도 |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US10865793B2 (en) | 2016-12-06 | 2020-12-15 | Air Squared, Inc. | Scroll type device having liquid cooling through idler shafts |
| US20200025199A1 (en) | 2018-07-17 | 2020-01-23 | Air Squared, Inc. | Dual drive co-rotating spinning scroll compressor or expander |
| US11530703B2 (en) | 2018-07-18 | 2022-12-20 | Air Squared, Inc. | Orbiting scroll device lubrication |
| US11473572B2 (en) | 2019-06-25 | 2022-10-18 | Air Squared, Inc. | Aftercooler for cooling compressed working fluid |
| US11898557B2 (en) | 2020-11-30 | 2024-02-13 | Air Squared, Inc. | Liquid cooling of a scroll type compressor with liquid supply through the crankshaft |
| US11885328B2 (en) | 2021-07-19 | 2024-01-30 | Air Squared, Inc. | Scroll device with an integrated cooling loop |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001420A (en) | 1968-12-12 | 1977-01-04 | Science Union Et Cie, Societe Francaise De Recherche Medical | Thiazolyl benzoic acid compounds |
| GB1308028A (en) | 1970-06-12 | 1973-02-21 | Science Union & Cie | Thiazolylbenzoic acid derivatives and a process for their manufactur |
| JPS4932853A (no) | 1972-07-27 | 1974-03-26 | ||
| US3939115A (en) * | 1974-10-02 | 1976-02-17 | Eastman Kodak Company | Polychromophoric ultraviolet stabilizers and their use in organic compositions |
| US4043973A (en) | 1974-10-02 | 1977-08-23 | Eastman Kodak Company | Multichromophoric ultraviolet stabilizers for organic compositions |
| US4164480A (en) | 1978-01-09 | 1979-08-14 | Eastman Kodak Company | Polychromophoric ultraviolet stabilizers and their use in organic compositions |
| SU1078859A1 (ru) | 1982-03-31 | 1997-10-20 | Б.М. Красовицкий | 2-(5-фенилоксазолил-2)-5-(5-арилоксазолил-2)-бензойные кислоты в качестве органических люминофоров сине-зеленого свечения в органических растворителях и водной среде |
| JPH0725754B2 (ja) * | 1986-01-30 | 1995-03-22 | 富山化学工業株式会社 | 新規なチアゾール化合物またはその塩 |
| JP2524786B2 (ja) * | 1987-12-15 | 1996-08-14 | コニカ株式会社 | 直接ポジハロゲン化銀カラ―写真感光材料 |
| DE3903993A1 (de) | 1989-02-10 | 1990-08-16 | Basf Ag | Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus |
| JP2941937B2 (ja) | 1990-01-25 | 1999-08-30 | キヤノン株式会社 | 新規化合物、これを含む液晶組成物及びこれを使用した液晶素子並びに表示装置 |
| JPH04154773A (ja) * | 1990-10-15 | 1992-05-27 | Green Cross Corp:The | チアゾール誘導体 |
| EP0513387B1 (en) | 1990-11-30 | 2000-03-01 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivatives as active oxygen inhibitors |
| US5639770A (en) | 1992-05-29 | 1997-06-17 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivatives |
| JP3385387B2 (ja) * | 1992-05-29 | 2003-03-10 | 大塚製薬株式会社 | チアゾール誘導体 |
| US5342851A (en) | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
| DE4302051A1 (de) * | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| PL183233B1 (pl) | 1995-02-24 | 2002-06-28 | Basf Ag | Nowe pochodne pirazol-4-ilo-benzoilu, sposób wytwarzania nowych pochodnych pirazol-4-ilo-benzoilu i środek chwastobójczy |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| JP3865829B2 (ja) | 1995-09-21 | 2007-01-10 | 株式会社医薬分子設計研究所 | レチノイド作用増強性化合物 |
| ES2124167B1 (es) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| WO1998008830A1 (de) * | 1996-08-26 | 1998-03-05 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazol-derivate als selektive inhibitoren der pde-iv |
| JP4300373B2 (ja) * | 1996-09-30 | 2009-07-22 | 大塚製薬株式会社 | サイトカイン産生抑制剤及び接着抑制剤 |
| AUPO691897A0 (en) * | 1997-05-21 | 1997-06-12 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
-
1999
- 1999-06-30 KR KR1020007014995A patent/KR20010053282A/ko not_active Withdrawn
- 1999-06-30 IL IL14042299A patent/IL140422A0/xx unknown
- 1999-06-30 CN CN99810103A patent/CN1314899A/zh active Pending
- 1999-06-30 US US09/720,644 patent/US6545009B1/en not_active Expired - Fee Related
- 1999-06-30 SK SK2018-2000A patent/SK20182000A3/sk unknown
- 1999-06-30 AU AU43947/99A patent/AU4394799A/en not_active Abandoned
- 1999-06-30 CA CA002332178A patent/CA2332178A1/en not_active Abandoned
- 1999-06-30 WO PCT/JP1999/003520 patent/WO2000001679A1/ja not_active Ceased
- 1999-06-30 ID IDW20010004D patent/ID29247A/id unknown
- 1999-06-30 BR BR9911752-5A patent/BR9911752A/pt not_active Application Discontinuation
- 1999-06-30 HU HU0102470A patent/HUP0102470A3/hu unknown
- 1999-06-30 EP EP99926853A patent/EP1092711A4/en not_active Withdrawn
- 1999-06-30 PL PL99345247A patent/PL345247A1/xx not_active Application Discontinuation
-
2000
- 2000-12-19 ZA ZA200007635A patent/ZA200007635B/en unknown
- 2000-12-27 NO NO20006667A patent/NO20006667L/no not_active Application Discontinuation
- 2000-12-28 LV LVP-00-177A patent/LV12633B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102470A3 (en) | 2002-05-28 |
| SK20182000A3 (sk) | 2001-08-06 |
| US6545009B1 (en) | 2003-04-08 |
| PL345247A1 (en) | 2001-12-03 |
| KR20010053282A (ko) | 2001-06-25 |
| CA2332178A1 (en) | 2000-01-13 |
| LV12633A (lv) | 2001-03-20 |
| LV12633B (en) | 2001-07-20 |
| ID29247A (id) | 2001-08-16 |
| ZA200007635B (en) | 2002-01-02 |
| EP1092711A4 (en) | 2002-07-31 |
| WO2000001679A1 (en) | 2000-01-13 |
| AU4394799A (en) | 2000-01-24 |
| CN1314899A (zh) | 2001-09-26 |
| NO20006667D0 (no) | 2000-12-27 |
| BR9911752A (pt) | 2001-04-03 |
| HUP0102470A2 (hu) | 2002-04-29 |
| EP1092711A1 (en) | 2001-04-18 |
| IL140422A0 (en) | 2002-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20006667L (no) | Retinoid-relaterte reseptor funksjonsregulerende middel | |
| Cordeiro et al. | Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles | |
| Zhang et al. | TiCl4 promoted formal [3+ 3] cycloaddition of cyclopropane 1, 1-diesters with azides: synthesis of highly functionalized triazinines and azetidines | |
| Easmon et al. | Synthesis, structure− activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics | |
| Tong et al. | 6-Cyano analogues of bedaquiline as less lipophilic and potentially safer diarylquinolines for tuberculosis | |
| Hasegawa et al. | Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists | |
| Huang et al. | Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles | |
| Tasaka et al. | Synthesis and structure–activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance | |
| Ishikawa et al. | Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators | |
| AU2004276252B2 (en) | Therapeutic agents useful for treating pain | |
| ATE303387T1 (de) | Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus | |
| TNSN06315A1 (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes | |
| Hunt et al. | Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat | |
| Tanaka et al. | Synthesis of anilino-monoindolylmaleimides as potent and selective PKCβ inhibitors | |
| Sriram et al. | Antituberculous activity of some aryl semicarbazone derivatives | |
| Asaki et al. | Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors | |
| Ichikawa et al. | Discovery of DF-461, a potent squalene synthase inhibitor | |
| Papeo et al. | A new glycociamidine ring precursor: Syntheses of (Z)-hymenialdisine,(Z)-2-debromohymenialdisine, and (±)-endo-2-debromohymenialdisine | |
| CA2701853A1 (en) | Metabotropic glutamate receptor modulators for the treatment of parkinson's disease | |
| Gaykar et al. | Synthesis of Trisubstituted Oxazoles via Aryne Induced [2, 3] Sigmatropic Rearrangement–Annulation Cascade | |
| Bennett et al. | Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain | |
| Fang et al. | Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors | |
| Pati et al. | Synthesis of functionalized arylacetamido-2-pyridones through ortho-C (sp2)–H-activated installation of olefins and alkynes | |
| Shcherbakov et al. | Hetero-Tetradehydro-Diels–Alder Cycloaddition of Enynamides and Cyanamides: Gold-Catalyzed Generation of Diversely Substituted 2, 6-Diaminopyridines | |
| Vachal et al. | Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |